VivoSeq
Cardiovascular

Left Ventricular Systolic Dysfunction

1

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Left Ventricular Systolic Dysfunction is an early-stage landscape with 1 program across 2 companies. The most active players are Bayer, Tenax Therapeutics, Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 3T

Tenax Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Finerenone

Bayer

Approved
No programs

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Unknown status1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
Unknown status·AArmaron Bio Pty Ltd·Phase 2·NCT02557217·120 enrolled
Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
Completed·TTenax Therapeutics, Inc.·Phase 3·NCT02025621·882 enrolled
A Phase 3, Single-arm, Open-label Extension Study to Evaluate the Safety of Finerenone in Addition to Standard of Care, in Pediatric Heart Failure Patients, From Birth to 18 Years of Age, With Left Ventricular Systolic Dysfunction (LVSD)
Recruiting·Bayer logoBayer·Phase 3·NCT07192952·117 enrolled
Simplified Assessment of Left Ventricular Systolic Function in Septic Shock Patients
Completed·CCentre Hospitalier Universitaire, Amiens·N/A·NCT04963686·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)